Gene Therapy - the next frontier in medicine
Our mission is to solve the biggest hurdle to gene therapy - delivery
Get in touchWhat we do:
Our mission is to harness the power of AI for non-viral gene delivery
Programmable, targeted, and safe polymer nanoparticles (PNPs) for a broad range of modalities and indications.
Innovate by design. Do great science. Be curious and courageous. Embrace change. Better humanity.
These are the values of our team of world-class scientists, engineers, and computational experts share as we strive to realize our vision: to redefine the boundaries of what's possible in gene delivery.
Effective gene delivery is essential for therapeutic break-throughs. Powered by our AI-driven platform - SAYER - we're building the next generation of non-viral delivery vehicles for a new wave of genetic medicines.
Who we are:
Founding Team
Biotech founders and innovators at the interface of materials science and engineering, biology, and computation
Sean Kevlahan
Co-founder and CEO
Sean Kevlahan, with a PhD in Chemical Engineering, is a seasoned product-driven entrepreneur. He co-founded and leads Nanite after propelling Quad Technologies from inception to a lucrative acquisition by Bio-Techne in 2018. His leadership of Bio-Techne's cell and gene therapy division through 2021 exemplifies his drive to transform biotech innovations into real solutions. Sean is compelled to solve complex ‘last mile’ challenges for cell and gene therapy.
Shashi Murthy
Co-founder and CTO
Shashi Murthy, with a PhD in polymer science from MIT, is a recovering academic and co-founder of Quad Technologies. He also founded Flaskworks, where he pioneered complex high-throughput screening and biotech automation workflows. His work bridges engineering and biotechnology and led to the acquisition of Quad (Bio-Techne) and Flaskworks (Northwest Bio). Shashi is committed to shaping the future of industrial biotech innovation.
Thomas Neenan
Co-founder and CBO
Thomas Neenan, with a PhD in the chemistry of materials, has spent his career exploring the boundaries between materials science and biology, generally in an entrepreneurial setting. Recent adventures include co-founding Panbela Therapeutics (NASDAQ: PBLA) and AbFero Pharmaceuticals (acquired by Pharmacosmos). Thomas is convinced of the potential of materials science to solve some of the most difficult questions in genetic medicine.
Felipe Oviedo
Head of ML / AI
Felipe Oviedo, PhD, is an MIT-educated scientist working at the interface of materials science and artificial intelligence. Previously, while at Microsoft and CERN, he worked on AI applied to scientific and engineering problems. Throughout his career, Felipe has been at the forefront of the fusion of machine learning with materials science and biology, leading to novel insights in computation-driven therapeutics design.
Jared Van Reet
Senior Research Associate
Teresa Tamayo
ML Scientist
John Fisher
Senior Scientist
Shannon Peterson
Scientist
Jeff Ting
Senior Scientist
Suteja Patil
ML Engineer
Aldo Nascimento
Principal Scientist
Rakshitha Miskin
Scientist
Nate Snell
Scientist
Sue Connolly
HR Manager
Supporters
Let’s talk about the possibilities
Learn more about our non-viral, fit for purpose delivery vehicles
Get in touch